tiprankstipranks
Trending News
More News >
Beauty Farm Medical & Health Industry, Inc. (HK:2373)
:2373
Hong Kong Market

Beauty Farm Medical & Health Industry, Inc. (2373) AI Stock Analysis

Compare
2 Followers

Top Page

HK:2373

Beauty Farm Medical & Health Industry, Inc.

(2373)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
HK$27.00
▲(2.43% Upside)
Beauty Farm Medical & Health Industry, Inc. demonstrates strong financial performance with robust revenue growth and profitability. However, the technical analysis indicates a bearish trend, which weighs down the overall score. The valuation is fair, with a reasonable P/E ratio and a modest dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Revenue Growth
Strong revenue growth indicates expanding market reach and effective business strategies, supporting long-term sustainability and competitiveness.
Cash Generation
Robust cash generation enhances liquidity and operational efficiency, providing financial flexibility for future investments and growth.
Profitability Margins
Stable and improving profitability margins reflect effective cost management and operational efficiency, supporting long-term financial health.
Negative Factors
Equity Ratio
A lower equity ratio indicates potential reliance on debt, which could limit financial flexibility and increase risk during economic downturns.
EBITDA Margin Decline
A declining EBITDA margin may signal rising operational costs or inefficiencies, which could impact profitability if not addressed.
Bearish Technical Trend
A persistent bearish trend may reflect underlying market concerns or challenges, potentially affecting investor confidence and capital access.

Beauty Farm Medical & Health Industry, Inc. (2373) vs. iShares MSCI Hong Kong ETF (EWH)

Beauty Farm Medical & Health Industry, Inc. Business Overview & Revenue Model

Company DescriptionBeauty Farm Medical & Health Industry, Inc. (2373) is a leading player in the healthcare and beauty sectors, specializing in providing innovative medical aesthetic solutions. The company operates through various segments, including skin care, body contouring, and wellness services. Its core offerings encompass advanced aesthetic treatments, medical-grade skincare products, and personalized wellness programs aimed at enhancing overall health and beauty for its clientele.
How the Company Makes MoneyBeauty Farm Medical & Health Industry, Inc. generates revenue primarily through a diverse range of services and product sales. Key revenue streams include aesthetic treatment services, which encompass procedures like laser treatments, injectables, and skin rejuvenation therapies. Additionally, the company benefits from the sale of proprietary skincare products designed to complement its treatments. Significant partnerships with medical professionals and wellness experts enhance its service offerings and draw in a robust customer base. The company may also engage in strategic collaborations with beauty brands or health organizations to expand its market reach and improve service delivery, contributing positively to its earnings.

Beauty Farm Medical & Health Industry, Inc. Financial Statement Overview

Summary
Beauty Farm Medical & Health Industry, Inc. showcases strong financial health with consistent revenue and profit growth. The company maintains solid profitability margins and effective cost management. The balance sheet is stable with moderate leverage and impressive return on equity, although there is room to enhance the equity ratio. Cash flow generation is robust, indicating strong liquidity and operational efficiency.
Income Statement
85
Very Positive
The company demonstrated solid revenue growth, increasing from HK$2,145 million in 2023 to HK$2,572 million in 2024, a growth rate of approximately 20%. Gross profit margin improved to 46.2%, reflecting efficient cost management. Net profit margin remained stable at around 8.9%, showcasing consistent profitability. The EBIT margin improved slightly to 12.5%, and EBITDA margin decreased to 16.6%, indicating healthy operational performance but with some potential reduction in operational efficiency.
Balance Sheet
78
Positive
The debt-to-equity ratio stands at 0.77, indicating moderate leverage. Return on equity is strong at 24.2%, driven by robust net income relative to equity. The equity ratio is 22.1%, suggesting a stable capital structure but with room for improvement in equity financing. Overall, the balance sheet demonstrates financial stability with manageable levels of debt.
Cash Flow
82
Very Positive
Free cash flow grew significantly from HK$466 million in 2023 to HK$797 million in 2024, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 3.49, and the free cash flow to net income ratio is 3.49, both reflecting efficient cash conversion and strong liquidity. These metrics suggest robust cash flow health and effective operational cash management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.89B2.57B2.15B1.64B1.78B1.50B
Gross Profit1.38B1.19B977.10M717.84M833.79M700.02M
EBITDA497.57M427.49M644.82M452.43M554.51M473.71M
Net Income268.72M228.46M215.66M103.11M193.47M150.96M
Balance Sheet
Total Assets4.31B4.28B3.30B2.50B2.48B2.10B
Cash, Cash Equivalents and Short-Term Investments2.00B1.83B1.57B910.63M1.08B801.92M
Total Debt779.08M730.59M563.12M525.50M515.46M515.69M
Total Liabilities3.38B3.30B2.47B2.29B2.21B1.96B
Stockholders Equity881.02M944.64M801.90M188.75M257.36M140.87M
Cash Flow
Free Cash Flow1.04B682.44M466.27M241.21M536.76M613.03M
Operating Cash Flow984.28M796.63M625.51M382.00M669.93M680.53M
Investing Cash Flow-394.38M-340.85M-711.18M53.63M-385.35M-368.94M
Financing Cash Flow-325.44M-223.36M133.74M-432.82M-271.06M-273.33M

Beauty Farm Medical & Health Industry, Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price26.36
Price Trends
50DMA
28.52
Negative
100DMA
31.06
Negative
200DMA
26.04
Positive
Market Momentum
MACD
-0.52
Negative
RSI
49.93
Neutral
STOCH
76.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2373, the sentiment is Neutral. The current price of 26.36 is above the 20-day moving average (MA) of 25.61, below the 50-day MA of 28.52, and above the 200-day MA of 26.04, indicating a neutral trend. The MACD of -0.52 indicates Negative momentum. The RSI at 49.93 is Neutral, neither overbought nor oversold. The STOCH value of 76.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2373.

Beauty Farm Medical & Health Industry, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$6.20B21.1231.23%1.97%28.53%22.34%
66
Neutral
HK$1.46B5.0420.47%4.89%-3.56%-17.45%
66
Neutral
HK$6.92B18.7214.86%2.57%16.41%32.97%
62
Neutral
HK$7.89B15.986.78%-13.92%-36.32%
55
Neutral
HK$6.89B-6.61-9.67%2.37%-8.56%-403.12%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
HK$94.15M-1.32-51.07%-20.66%-77.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2373
Beauty Farm Medical & Health Industry, Inc.
26.80
10.08
60.29%
HK:1526
Rici Healthcare Holdings Ltd.
0.94
-0.25
-21.01%
HK:1951
Jinxin Fertility Group Ltd.
2.51
-0.32
-11.31%
HK:2135
Raily Aesthetic Medicine International Holdings Limited
0.17
0.06
54.63%
HK:2273
Gushengtang Holdings Limited
29.44
-1.89
-6.03%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
12.79
-1.71
-11.79%

Beauty Farm Medical & Health Industry, Inc. Corporate Events

Beauty Farm Medical & Health Industry Inc. EGM Resolution Passed
Dec 5, 2025

Beauty Farm Medical & Health Industry Inc. announced that the resolution proposed at their Extraordinary General Meeting (EGM) held on December 5, 2025, was passed as an ordinary resolution. The resolution involved the approval of a Share Purchase Agreement and the issuance and allotment of Consideration Shares under a Specific Mandate. The resolution received overwhelming support, with 99.54% of votes in favor, reflecting strong shareholder confidence in the company’s strategic decisions.

Beauty Farm Medical & Health Industry Inc. Boosts Shareholder Confidence with Share Purchases
Dec 3, 2025

Beauty Farm Medical and Health Industry Inc. announced an increase in shareholding by non-executive director Ms. Li Fangyu, who acquired an additional 52,000 shares, reflecting her confidence in the company’s future prospects. Additionally, the company repurchased 74,500 shares, signaling management’s belief in the undervaluation of its stock and commitment to enhancing shareholder value. These actions are expected to positively impact the company’s market position and shareholder returns.

Beauty Farm Director Increases Shareholding, Signaling Confidence
Dec 2, 2025

Beauty Farm Medical & Health Industry Inc. announced an increase in shareholding by non-executive director Ms. Li Fangyu, who acquired 21,000 ordinary shares, representing approximately 0.01% of the total issued shares. This acquisition reflects her confidence in the company’s future prospects and ensures compliance with public float requirements on the Hong Kong Stock Exchange.

Beauty Farm Enhances Market Confidence with Shareholder Moves
Dec 1, 2025

Beauty Farm Medical and Health Industry Inc. announced an increase in shareholding by a non-executive director, Ms. Li Fangyu, who acquired 41,500 shares, reflecting her confidence in the company’s future. Additionally, the company repurchased 80,000 shares on the market, as part of a broader repurchase strategy, to enhance its market value and shareholder returns, demonstrating management’s belief in the company’s intrinsic value.

Beauty Farm Expands with Naturade Brand Acquisition
Dec 1, 2025

Beauty Farm Medical & Health Industry Inc. announced a supplemental update regarding its acquisition of equity interest in businesses operating under the Naturade brand. The acquisition is expected to enhance operational control, strengthen brand positioning, and improve financial performance through economies of scale. The company views this acquisition as a strategic move to expand its geographical footprint in the Greater Bay Area, leveraging its dual beauty and wellness model to increase revenue and profitability.

Beauty Farm Medical & Health Industry Inc. Announces Share Repurchase
Nov 28, 2025

Beauty Farm Medical & Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 80,000 shares at an average price of HK$25.09 per share, totaling approximately HK$2,007,420. The Board believes the repurchase reflects confidence in the company’s long-term value, aiming to enhance market value and shareholder returns.

Beauty Farm Medical & Health Industry Inc. Announces Share Repurchase
Nov 27, 2025

Beauty Farm Medical & Health Industry Inc. announced a voluntary on-market share repurchase, buying back 100,000 shares for approximately HK$2,379,520. This move, part of a broader repurchase strategy, reflects the board’s confidence in the company’s long-term value and aims to enhance shareholder returns and market value.

Beauty Farm Expands with Naturade Brand Acquisition
Nov 18, 2025

Beauty Farm Medical & Health Industry Inc. announced the acquisition of equity interests in subsidiaries operating under the Naturade brand, with a total consideration of RMB40.0 million. This acquisition will add 19 new direct stores to the company’s portfolio, enhancing its coverage in core cities of the Greater Bay Area and significantly boosting its revenue. The transaction is considered a connected transaction under the Hong Kong Stock Exchange’s Listing Rules but is exempt from certain requirements due to its fair and reasonable terms.

Beauty Farm Medical & Health Industry Inc. Announces Acquisition Plans
Nov 16, 2025

Beauty Farm Medical & Health Industry Inc. has announced an extraordinary general meeting to approve a share purchase agreement for acquiring 100% of Shanghai Siyanli Industrial Co., Ltd. The transaction involves issuing 15,798,147 shares at HK$28.71 each to the vendors, pending approval from the Hong Kong Stock Exchange, which could enhance the company’s market position and expand its operational capabilities.

Beauty Farm Announces HK$1.2 Billion Shareholder Return Plan
Nov 4, 2025

Beauty Farm Medical & Health Industry Inc. has announced a plan to enhance shareholder value by allocating up to HK$1.2 billion over the next three years for dividends and share repurchases. The company intends to fund these initiatives through internal resources, ensuring no adverse impact on its working capital. The execution of these plans will depend on the company’s performance and market conditions, with no guarantees on timing or amounts.

Beauty Farm Medical Announces Share Repurchase to Boost Shareholder Value
Oct 31, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 40,000 shares, totaling approximately HK$1,236,230, as part of a broader repurchase strategy. The Board believes this move reflects confidence in the company’s long-term value and aims to enhance shareholder returns, although future repurchases depend on market conditions.

Beauty Farm Announces Director’s Share Purchase and Share Repurchase
Oct 30, 2025

Beauty Farm Medical & Health Industry, Inc. announced an increase in shareholding by a non-executive director, Ms. Yi Lin, who purchased 61,000 shares, reflecting her confidence in the company’s future. Additionally, the company conducted an on-market share repurchase of 30,000 shares, indicating management’s belief in the long-term value of the enterprise and aiming to enhance capital market value and shareholder returns.

Beauty Farm Medical and Health Industry Inc. Announces Share Repurchase
Oct 28, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary share repurchase, acquiring 30,000 shares on October 28, 2025, as part of a broader initiative that has seen the repurchase of 445,000 shares since October 15, 2025. The board believes the current share price undervalues the company’s intrinsic worth and prospects, and the repurchase is intended to enhance market value and shareholder returns.

Beauty Farm Medical and Health Industry Inc. Announces Strategic Share Repurchase
Oct 27, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary repurchase of 40,000 shares on October 27, 2025, at an average price of HK$31.10 per share, totaling approximately HK$1,244,090. This move is part of a broader repurchase strategy that has seen 415,000 shares repurchased since October 15, 2025, for a total of HK$13,224,850. The board believes the current trading price undervalues the company’s intrinsic worth and business prospects, and this repurchase reflects confidence in the company’s long-term value, aiming to enhance market value and shareholder returns.

Beauty Farm Medical and Health Industry Inc. Announces Share Repurchase
Oct 24, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, buying back 50,000 shares at an average price of HK$31.72 each, totaling approximately HK$1,585,810. This action is part of a broader repurchase strategy, with a total of 375,000 shares repurchased since October 15, 2025, for about HK$11,980,760. The board believes the current share price undervalues the company’s intrinsic worth and prospects, and the repurchase is expected to enhance market value and shareholder returns.

Beauty Farm Medical Announces Share Repurchase to Boost Shareholder Value
Oct 23, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 65,000 shares at an average price of HK$30.33 per share, totaling approximately HK$1,971,240. This move, part of a broader repurchase strategy totaling 325,000 shares, reflects the board’s confidence in the company’s long-term value and aims to enhance shareholder returns by capitalizing on the current undervaluation of its stock.

Beauty Farm Medical Announces Strategic Share Repurchase
Oct 21, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 50,000 shares for approximately HK$1,565,530. The Board believes the current share price undervalues the company and sees the repurchase as a demonstration of confidence in its long-term value, aiming to enhance market value and shareholder returns.

Beauty Farm Announces Strategic Share Repurchase
Oct 20, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 70,000 shares, totaling approximately HK$2,209,470, as part of a broader repurchase strategy that has seen 210,000 shares bought back since October 15, 2025. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its market value and shareholder returns.

Beauty Farm Medical & Health Industry Inc. Announces Share Repurchase to Boost Market Value
Oct 17, 2025

Beauty Farm Medical & Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 60,000 shares for approximately HK$1,942,870, reflecting management’s confidence in the company’s long-term value. The board believes the current share price undervalues the company’s prospects, and this repurchase aims to enhance the company’s market value and shareholder returns.

Beauty Farm Medical Announces Strategic Share Repurchase
Oct 16, 2025

Beauty Farm Medical and Health Industry Inc. announced a recent on-market share repurchase, acquiring 30,000 shares for approximately HK$1,011,030. The Board believes the current share price undervalues the company’s intrinsic worth and business prospects, and the repurchase reflects confidence in its long-term value, aiming to enhance market value and shareholder returns.

Beauty Farm Medical & Health Industry Announces Share Repurchase
Oct 15, 2025

Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 50,000 shares at an average price of HK$33.90 per share, totaling approximately HK$1,694,810. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its market value and shareholder returns. The repurchase was conducted under a mandate allowing the company to buy back up to 10% of its issued shares.

Beauty Farm Announces Major Acquisition of Shanghai Siyanli Industrial
Oct 15, 2025

Beauty Farm Medical & Health Industry, Inc. has announced a major transaction involving the acquisition of 100% of the issued shares in Shanghai Siyanli Industrial for RMB1,250.0 million. This acquisition will result in Shanghai Siyanli Industrial becoming an indirect wholly-owned subsidiary of Beauty Farm, with its results, assets, and liabilities consolidated into the group’s accounts. The transaction involves the issuance of consideration shares, which will be subject to shareholder approval at an Extraordinary General Meeting (EGM). The acquisition is classified as a major transaction under the Listing Rules, necessitating certain reporting and approval requirements. Shareholders and potential investors are advised to exercise caution as the acquisition is subject to conditions precedent and may not proceed.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 30, 2025